Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?

Author(s): Marjorie Argollo, Gionata Fiorino*, Daniela Gilardi, Federica Furfaro, Giulia Roda, Laura Loy, Mariangela Allocca, Laurent Peyrin-Biroulet and Silvio Danese

Volume 25, Issue 1, 2019

Page: [7 - 12] Pages: 6

DOI: 10.2174/1381612825666190312113610

Price: $65

Abstract

Introduction: Biosimilars present a considerable potential to reduce costs related to clinical management allowing health-care providers to reinvest this money, leading to a wider access to an effective biological treatment with monoclonal antibodies (mAb). Infliximab biosimilars have already been incorporated in daily clinical practice and are currently used in all indications for which the reference product (RP) was approved.

Areas covered: In the next few years, also adalimumab biosimilars will become available for the treatment of inflammatory bowel disease (IBD). In fact, several of them (ABP501, BI 695501, GP2017, and SB5) have been approved by the European Medicines Agency (EMA) with the same indications of the reference product (Humira ®). Initial preclinical data proved a strong similarity between all biosimilars and the RP. Moreover, phase 3 studies in rheumatoid arthritis and psoriasis showed no differences in terms of efficacy, safety, and immunogenicity. Data on IBD patients are urgently needed.

Expert opinion: Biosimilars of adalimumab showed equivalent clinical efficacy to the RP in other immunemediated diseases. However, defining the ideal patient’s profile to receive or to be switched to a biosimilar, choosing one biosimilar vs. another, or cross-switching among biosimilars, will become the next challenge in IBD.

Keywords: Adalimumab, biosimilar, Crohn's disease, inflammatory bowel disease, ulcerative colitis, monoclonal antibodies.

« Previous Next »
[1]
Harbord M, Eliakim R, Bettenworth D, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohn’s Colitis 2017; 11(7): 769-84.
[2]
Gomollon F, Dignass A, Annese V, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohn’s Colitis 2017; 11(1): 3-25.
[3]
Blackstone EA, Joseph PF. The Economics of Biosimilars. Am Health Drug Benefits 2013; 6(8): 469-78.
[4]
Research and Markets. Global Monoclonal Antibodies Market - by Type, Application, Region - Market Size, Demand Forecasts, Company Profiles, Industry Trends and Updates (2017-2023) 2018.[cited 2018 Aug 17]; Available from: https://www. researchandmarkets.com/research/mmpjv5/global_131_33?w=4.
[5]
Technavio.. Global Anti-inflammatory Therapeutics Market 2017- 2021 2017.[cited 2018 Aug 17]; Available from: https:// www.technavio.com/report/global-anti-inflammatory-therapeutics-market?utm_source=t2&utm_medium=bw&utm_campaign=businesswire.
[6]
www.statista.comPotential savings due to biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros) 2018.[cited 2018 Aug 17]; Available from: https://www.statista.com/statistics/700008/potential-savings-due-to-biosimilars-in-eu5-and-us/.
[7]
Norman P. Humira: the impending patent battles over adalimumab biosimilars. Pharm Pat Anal 2016; 5(3): 141-5.
[8]
European Medicine Agency. Humira - EPAR Scientific Discussion. 2006.[cited 2018 Aug 21]; Available from: http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000481/WC500050867.pdf.
[9]
European Medicine Agency. Amgevita - Public Assessment Report. 2017.[cited 2018 Aug 21]; Available from: http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004212/WC500225277.pdf.
[10]
European Medicine Agency. Solymbic - Public Assessment Report. 2018.[cited 2018 Aug 21]; Available from: http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004373/WC500225367.pdf.
[11]
European Medicine Agency. Cyltezo - Public Assessment Report 2017.[cited 2018 Aug 21]; Available from: http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004319/WC500238609.pdf.
[12]
European Medicine Agency. Hyrimoz - Public Assessment Report. 2018.[cited 2018 Aug 21]; Available from: http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004320/WC500252824.pdf.
[13]
European Medicine Agency. Imraldi - Public assessment report. 2017.[cited 2018 Aug 21]; Available from: http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004279/WC500233922.pdf.
[14]
Liu J, Eris T, Li C, Cao S, Kuhns S. Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab. Bio- Drugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2016; 30(4): 321-8. Epub 2016/07/28.
[15]
Velayudhan J, Chen YF, Rohrbach A, et al. Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab. BioDrugs 2016; 30(4): 339-51.
[16]
Kaur P, Chow V, Zhang N, Moxness M, Kaliyaperumal A, Markus R. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis 2017; 76(3): 526-33.
[17]
Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol 2017; 76(6): 1093-102.
[18]
Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2017; 177(6): 1562-74.
[19]
Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis 2017; 76(10): 1679-87.
[20]
Cohen S, Pablos JL, Wang H, et al. ABP 501 biosimilar to adalimumab: final safety, immunogenicity, and efficacy results from an open-label extension study. Ann Rheum Dis 2017; 76(Suppl. 2): 834.
[21]
Wynne C, Altendorfer M, Sonderegger I, et al. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE(R)-PK) in healthy subjects. Expert Opin Investig Drugs 2016; 25(12): 1361-70.
[22]
Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis 2018; 77(6): 914-21.
[23]
Dasilva A, Kronthaler U, Hofmann HP, et al. Comparison of Nonclinical Pharmacology, Pharmacodynamics and E. Arthritis Rheumatol 2016; 68 (Suppl. 10).
[24]
Schuck E, Jauch J, Balfour A, et al. A Randomized, Open-Label, Single-Dose, Parallel-Group Trial to Determine the Pharmacokinetics, Safety and Immunogenicity of GP2017, a Proposed Adalimumab Biosimilar, Following a Single Subcutaneous Injection By an Autoinjector or Prefilled syringe in Healthy Male Subjects. Arthritis Rheumatol 2016; 68 (Suppl. 10).
[25]
Blauvelt A, Lacour JP, Fowler JF Jr, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol 2018; 179(3): 623-31.
[26]
Shin D, Lee Y, Kim H, Kornicke T, Fuhr R. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. J Clin Pharm Ther 2017; 42(6): 672-8.
[27]
Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. Arthritis Rheumatol 2018; 70(1): 40-8.
[28]
Weinblatt ME, Baranauskaite A, Dokoupilova E, et al. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results. Arthritis Rheumatol 2018; 70(6): 832-40.
[29]
Jamshidi A, Gharibdoost F, Vojdanian M, et al. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis. Arthritis Res Ther 2017; 19(1): 168.
[30]
Jani RH, Gupta R, Bhatia G, et al. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis 2016; 19(11): 1157-68.
[31]
Midha V, Mahajan R, Mehta V, et al. Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis. Intest Res 2018; 16(1): 83-9.
[32]
Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 2014; 160(10): 704-11.
[33]
Danese S, Fiorino G. Anti-TNF biosimilars in inflammatory bowel disease: searching the proper patient’s profile? Curr Med Chem 2019; 26(2): 280-7.
[34]
Harbord M, Annese V, Vavricka SR, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohn’s Colitis 2016; 10(3): 239-54.
[35]
Danese S, Fiorino G, Raine T, et al. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. J Crohn’s Colitis 2017; 11(1): 26-34.
[36]
European Medicine Agency. Zessly. 2018.cited 2018 Aug 17]; Available from: http://www.ema.europa.eu/docs/en_GB/document _library/EPAR_-_Summary_for_the_public/human/004647/ WC500249650.pdf.
[37]
Fiorino G, Manetti N, Armuzzi A, et al. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis 2017; 23(2): 233-43.
[38]
Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017; 389(10086): 2304-16.
[39]
Armuzzi A, Fiorino G, Variola A, et al. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflamm Bowel Dis 2019; 25(3): 568-79.

Rights & Permissions Print Cite
Article Metrics
59
18
3
1
© 2024 Bentham Science Publishers | Privacy Policy